Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 796 across all filing types
Latest filing 2025-04-23 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Regulatory Filings Classification · 1% confidence The document is a press release issued by Pharming Group N.V. announcing a positive recommendation from the National Institute for Health and Care Excellence (NICE) for their drug Joenja (leniolisib). It details the regulatory milestone, provides quotes from management and medical professionals, and includes standard corporate boilerplate information. It does not constitute a full financial report, audit, or proxy statement, but rather a regulatory announcement regarding company operations and product approval status. Therefore, it falls under the 'Regulatory Filings' category as a general corporate announcement.
2025-04-23 Dutch
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Regulatory Filings Classification · 1% confidence The document is a press release issued by Pharming Group N.V. announcing a positive recommendation from the National Institute for Health and Care Excellence (NICE) regarding the reimbursement of their drug, Joenja (leniolisib). It follows the standard format of a corporate press release, including a headline, dateline, quotes from executives, background information on the product and disease, and contact information. As it is a general regulatory announcement regarding company operations and product status that does not fit into more specific categories like financial results or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-04-23 English
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Regulatory Filings Classification · 1% confidence The document is a press release dated April 23, 2025, announcing that Pharming Group N.V. received positive final guidance from NICE recommending Joenja® (leniolisib) for reimbursement within the NHS in England and Wales. This type of announcement, detailing a regulatory or reimbursement milestone (NICE guidance/MHRA approval) for a specific drug, is a standard corporate communication. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), a Call Transcript (CT), or a formal filing like a DEF 14A or DVA. It is a specific corporate update regarding product access and regulatory status. Since it is a press release announcing a significant business/regulatory event rather than a formal SEC filing or a general regulatory filing (RNS), and it doesn't fit the other specific categories (like DIV, CAP, MANG), the most appropriate classification is a general Regulatory Filing (RNS) as a catch-all for significant, non-standardized corporate news releases, although it strongly resembles an Earnings Release (ER) in format, it is focused on reimbursement, not financial results. Given the options, RNS serves as the best fit for a non-financial, non-governance, non-transactional corporate announcement that is regulatory in nature (NICE guidance). However, if we consider the context of drug approval/reimbursement news, it is often categorized under general corporate news. Since it is not an ER (which focuses on financial results), RNS is the fallback for significant announcements.
2025-04-23 English
6-K
Foreign Filer Report
2025-04-03 English
20-F
Annual Report FY 2024
2025-04-03 English
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Report Publication Announcement Classification · 1% confidence The document is a short press release (approx. 2000 characters) announcing the publication and filing of the company's 2024 Annual Report and Form 20-F. It directs readers to the company website to access the actual reports. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2025-04-03 Dutch

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.